Detail akcie Telix Pharma Rg online

Business Summary: Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Telix Pharmaceuticals Ltd revenues increased 63% to $390.4M. Net loss totaled $2.3M vs. income of $19.6M. Revenues reflect Manufacturing Solutions segment increase from $527K to $80.5M, Precision Medicine segment increase of 29% to $305.8M, Therapeutics segment increase of 41% to $4M, United States segment increase of 63% to $381.1M, China segment increase of 44% to $4.5M.